Oxo-aglaiastatin-Mediated Inhibition of Translation Initiation

Area of Science:

• Molecular Biology
• Oncology
• Drug Discovery

Background:

• Cancer cells often hijack the translation process, particularly via the PI3K/mTOR pathway, impacting translation initiation.
• Targeting eukaryotic initiation factor (eIF) 4F-dependent translation is a validated strategy to inhibit tumor growth and enhance chemotherapy.
• Rocaglates, derived from the Aglaia genus, are known inhibitors of eIF4A, the RNA helicase subunit of eIF4F.

Purpose of the Study:

• To evaluate synthetic derivatives of aglaiastatins and aglaroxin as inhibitors of the translation process.
• To investigate the potential of oxo-aglaiastatin as an anti-cancer agent.
• To determine the mechanism of action and synergistic potential of oxo-aglaiastatin.

Main Methods:

• In vitro and in vivo assays to assess translation inhibition.
• Testing of synthetic rocaglate derivatives, including oxo-aglaiastatin.
• Evaluation of synergistic effects with standard chemotherapies (doxorubicin, ABT-199, dexamethasone) in hematological cancer cells.
• Biochemical assays to confirm inhibition of eIF4A1 activity.

Main Results:

• The synthetic derivative oxo-aglaiastatin demonstrated potent inhibition of translation both in vitro and in vivo.
• Oxo-aglaiastatin exhibited synergistic effects when combined with doxorubicin, ABT-199, and dexamethasone in hematological cancer cells.
• The anti-cancer activity of oxo-aglaiastatin was confirmed to be due to the inhibition of eIF4A1 enzyme activity.

Conclusions:

• Oxo-aglaiastatin is a potent inhibitor of translation initiation by targeting eIF4A1.
• This compound represents a promising therapeutic candidate for hematological malignancies.
• Oxo-aglaiastatin's ability to synergize with existing treatments warrants further clinical investigation.